Literature DB >> 15749307

Applications of liposomes in ophthalmology.

Shehab Ebrahim1, Gholam A Peyman, Paul J Lee.   

Abstract

This review outlines the applications of liposomal formulations in ophthalmology. In ophthalmology, liposomes have been used to treat disorders of both the anterior and posterior segments. These include dry eyes, keratitis, corneal transplant rejection, uveitis, endophthalmitis, and proliferative vitreoretinopathy. Liposomes also have shown promise as vectors for genetic transfection and monoclonal antibody-directed vehicles. Furthermore, heat-activated liposomes have spurred research in focal laser and heat-induced release of liposomal drugs and dyes for selective drug delivery. These techniques have been useful in selective tumor and neovascular vessel occlusion, angiography, and retinal and choroidal blood-flow studies. Although verteporfin is the only liposomal drug currently approved for use in the eye, the benefits of liposomes will likely be applied widely in all treatment, diagnostic, and research aspects of ophthalmology in the future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15749307     DOI: 10.1016/j.survophthal.2004.12.006

Source DB:  PubMed          Journal:  Surv Ophthalmol        ISSN: 0039-6257            Impact factor:   6.048


  24 in total

1.  Stimulus-responsive liposomes as smart nanoplatforms for drug delivery applications.

Authors:  Parham Sahandi Zangabad; Soroush Mirkiani; Shayan Shahsavari; Behrad Masoudi; Maryam Masroor; Hamid Hamed; Zahra Jafari; Yasamin Davatgaran Taghipour; Hura Hashemi; Mahdi Karimi; Michael R Hamblin
Journal:  Nanotechnol Rev       Date:  2017-12-12       Impact factor: 7.848

2.  Light-activated nanoimpeller-controlled drug release in cancer cells.

Authors:  Jie Lu; Eunshil Choi; Fuyuhiko Tamanoi; Jeffrey I Zink
Journal:  Small       Date:  2008-04       Impact factor: 13.281

Review 3.  Advances in ocular drug delivery systems.

Authors:  Jennifer J Kang-Mieler; Kayla M Rudeen; Wenqiang Liu; William F Mieler
Journal:  Eye (Lond)       Date:  2020-02-18       Impact factor: 3.775

4.  Optimization of dexamethasone mixed nanomicellar formulation.

Authors:  Kishore Cholkar; Sudharshan Hariharan; Sriram Gunda; Ashim K Mitra
Journal:  AAPS PharmSciTech       Date:  2014-07-01       Impact factor: 3.246

Review 5.  Nanocarriers of nanotechnology in retinal diseases.

Authors:  Ali M Al-Halafi
Journal:  Saudi J Ophthalmol       Date:  2014-03-05

Review 6.  Recent patents on ophthalmic nanoformulations and therapeutic implications.

Authors:  Ann-Marie Ako-Adounvo; Ramesh C Nagarwal; Lais Oliveira; Sai H S Boddu; Xiang S Wang; Surajit Dey; Pradeep K Karla
Journal:  Recent Pat Drug Deliv Formul       Date:  2014

7.  Pentablock copolymer dexamethasone nanoformulations elevate MYOC: in vitro liberation, activity and safety in human trabecular meshwork cells.

Authors:  Vibhuti Agrahari; Guorong Li; Vivek Agrahari; Iris Navarro; Kristin Perkumas; Abhirup Mandal; W Daniel Stamer; Ashim K Mitra
Journal:  Nanomedicine (Lond)       Date:  2017-07-31       Impact factor: 5.307

8.  Antifungal activity of a liposomal itraconazole formulation in experimental Aspergillus flavus keratitis with endophthalmitis.

Authors:  André Ferraz Goiana Leal; Melyna Chaves Leite; Caroline Sanuzi Quirino Medeiros; Isabella Macário Ferro Cavalcanti; Almir Gonçalves Wanderley; Nereide Stela Santos Magalhães; Rejane Pereira Neves
Journal:  Mycopathologia       Date:  2014-11-28       Impact factor: 2.574

Review 9.  Pharmaceutical microscale and nanoscale approaches for efficient treatment of ocular diseases.

Authors:  I Bravo-Osuna; V Andrés-Guerrero; P Pastoriza Abal; I T Molina-Martínez; R Herrero-Vanrell
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

10.  Partially polymerized liposomes: stable against leakage yet capable of instantaneous release for remote controlled drug delivery.

Authors:  Guoting Qin; Zheng Li; Rongmin Xia; Feng Li; Brian E O'Neill; Jessica T Goodwin; Htet A Khant; Wah Chiu; King C Li
Journal:  Nanotechnology       Date:  2011-03-10       Impact factor: 3.874

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.